September 11, 2019Open Access

A clinico-genomic analysis of soft tissue sarcoma patients reveals CDKN2A deletion as a biomarker for poor prognosis

Key Points

Key points are not available for this paper at this time.

Abstract

Our clinico-genomic profiling of STS shows that CDKN2A deletion was the most prevalent DNA copy number aberration and was associated with poor prognosis.

Bookmark

View Full Paper

Cite This Study

Bui et al. (Wed,) studied this question.

synapsesocial.com/papers/69d6b2f88dca315383ed8965 https://doi.org/https://doi.org/10.1186/s13569-019-0122-5

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas2017 · 1,075 citations
2Analysis of the p16INK4, p14ARF, p15, TP53, and MDM2 Genes and Their Prognostic Implications in Osteosarcoma and Ewing Sarcoma2000 · 178 citations
3Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data1997 · 1,052 citations
4Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data1997 · 692 citations
5Clinical Trial Substantiates the Predictive Value of <b> <i>O-6-Methylguanine-DNA Methyltransferase</i> </b> Promoter Methylation in Glioblastoma Patients Treated with Temozolomide2004 · 791 citations

Bookmark

View Full Paper